Cartherics raises over $15 Million in oversubscribed private financing round to advance cell therapy programs
Posted: 19 December 2024 Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer and other diseases, is pleased to announce that it has successfully raised well over its target AU$15M…
Doherty Institute and the University of Calgary partner to award AU$175,000 in grant funding
Posted: 19 December 2024 Developing advanced rapid diagnostics for the mpox virus and consolidating global expertise in human organoids to aid pandemic therapeutic research are just two of the innovative projects being funded through the Melbourne-Calgary Collaborative Seed…
Starpharma receives positive feedback from FDA on DEP® SN38 clinical pathway for platinum-resistant ovarian cancer
Posted: 19 December 2024 Starpharma (ASX: SPL, US OTC: SPHRY), an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient, today announces a positive development regarding its DEP® SN38 (DEP®…
Stem Cells: Hope on the Horizon for Preterm Babies
Posted: 18 December 2024 Australian researchers have discovered a potential new lifeline for the tiniest and most vulnerable newborns. Scientists at Monash Children’s Hospital have successfully collected and reinfused umbilical cord blood cells in extremely premature babies, offering…
Cartherics awarded US$300K G-Rex Grant to accelerate clincial manufacturing of CAR-NK cell therapy
Posted: 18 December 2024 Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company focused on developing immune cell therapies for cancer and other diseases, is pleased to announce that it has been awarded a US$300K G-Rex grant to…
Australian Medtech Manufacturing Alliance strengthens with new steering group members announced
Monday 16 December 2024: Further bolstering Australia’s vision to see more local SME health technology procured domestically, Pathology Technology Australia (PTA), the Association of Healthcare Supply and Procurement Officers (AHSPO) and the Medical Technology Association of Australia (MTAA)…
4DMedical wins contract to supply lung imaging technology to US radiology company
Posted: 17 December 2024 4DMedical (ASX: 4DX) has been awarded a contract with US-based Imaging Partners of Orange County (IPOC) to provide computed tomography (CT) scans for lung ventilation (LVAS) and lung density (LDAf) analysis. The contract – the…
Weaponising exosomes for breast cancer treatment
Posted: 17 December 2024 INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce that it has successfully completed stage 1 of its development program for an exosome therapeutic for breast cancer. In this in vitro proof-ofconcept (POC) study,…
Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024
Posted: 16 December 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive clinical results from Cohort B of the TACTI-003…
BioMelbourne Network and AusBiotech welcome the Victorian Government’s Economic Growth Statement
Posted: 12 December 2024 BioMelbourne Network, Victoria’s leading industry association for organisations engaged in biotechnology, medical technology, and health innovation in Victoria and AusBiotech, Australia’s leading national industry association representing more than 3000 members across the life…
Positive new data and strong recruitment in pancreatic cancer trial
Posted: 11 December 2024 Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to report updated data from Company’s ongoing Phase 2a clinical trial. This trial is investigating the Company’s FAK inhibitor narmafotinib in combination with…
Ghana becomes first river blindness-endemic country to approve moxidectin
Posted: 10 December 2024 Medicines Development for Global Health (MDGH) announced today that the Ghana Food and Drugs Authority (FDA) has approved the marketing authorisation application for moxidectin 2 mg oral tablets for the treatment of river blindness (onchocerciasis)…
